Jing Li1, Jian Gu1. 1. College of Pharmacy, Southwest Minzu University, No.16 South 4th Section, 1st Ring Road, Chengdu, Sichuan 610041, PR China.
Abstract
AIM: We conducted a meta-analysis to systematically review the efficacy and safety of programmed cell death 1 (PD-1) inhibitors for advanced melanoma. STUDY DESIGN: The relevant studies of the randomized controlled trials in melanoma patients treated with PD-1 inhibitors were retrieved and the systematic evaluation was conducted. Databases were searched till June 2018. RESULTS: PD-1 inhibitors significantly improved the progression-free survival, overall survival and overall response rate in patients with advanced melanoma. Progression-free survival, overall survival and overall response rate did not vary significantly according to PD-L1 status, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations and type of drug, but varied significantly by control therapy. PD-1 inhibitors were associated with a decreased risk of adverse events compared with ipilimumab, but an increased risk of immune-related events compared with chemotherapy. CONCLUSION: The PD-1 inhibitors-containing therapy was efficacious in treating advanced melanoma.
AIM: We conducted a meta-analysis to systematically review the efficacy and safety of programmed cell death 1 (PD-1) inhibitors for advanced melanoma. STUDY DESIGN: The relevant studies of the randomized controlled trials in melanomapatients treated with PD-1 inhibitors were retrieved and the systematic evaluation was conducted. Databases were searched till June 2018. RESULTS: PD-1 inhibitors significantly improved the progression-free survival, overall survival and overall response rate in patients with advanced melanoma. Progression-free survival, overall survival and overall response rate did not vary significantly according to PD-L1 status, V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations and type of drug, but varied significantly by control therapy. PD-1 inhibitors were associated with a decreased risk of adverse events compared with ipilimumab, but an increased risk of immune-related events compared with chemotherapy. CONCLUSION: The PD-1 inhibitors-containing therapy was efficacious in treating advanced melanoma.
Authors: Thomas G P Grünewald; Thomas Knösel; Martin F Orth; Veit Leonhard Buecklein; Eric Kampmann; Marion Subklewe; Elfriede Noessner; Florencia Cidre-Aranaz; Laura Romero-Pérez; Fabienne Sophie Wehweck; Lars Lindner; Rolf Issels; Thomas Kirchner; Annelore Altendorf-Hofmann Journal: Cancer Immunol Immunother Date: 2020-03-28 Impact factor: 6.968
Authors: Laith Al-Showbaki; Michelle B Nadler; Alexandra Desnoyers; Fahad A Almugbel; David W Cescon; Eitan Amir Journal: J Cancer Date: 2021-05-19 Impact factor: 4.207